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1. Introduction
Andrographis paniculata, (Burm. f.) Wall. ex Nees, a herbaceous plant belonging to the Family
Acanthaceae, is one of the most commonly used medicinal plants in the traditional systems of
Unani and Ayurvedic medicines. It grows in hedge rows throughout the plains of India and is
also cultivated in gardens. It also grows in many other Asian countries and is used as a tradition‐
al herbal medicine in China, Hong Kong, the Philippines, Malaysia, Indonesia, and Thailand. It
is an annual plant of 1-3 ft high, also known as the “king of bitters”, being the aerial parts most
commonly used. A. paniculata have shown a broad range of pharmacological effects such as in‐
hibition of replication of the HIV virus, prevention of common cold, and antimalarial, antidiar‐
rheal,  antibacterial,  antihyperglycemic  effects,  suppression  of  various  cancer  cells,  and
principally anti-inflammatory properties. Andrographolide is the major labdane diterpenoid
isolated from A. paniculata and exhibits anti-inflammatory and anticancer activities, either in vi‐
tro or in vivo experimental models of inflammation and cancer. Several immunomodulatory re‐
sponses of andrographolide have been observed in in vitro studies, such as reduction of iNOS,
COX-2, NO, PGE2, TNF-alpha and IL-12 in macrophages and microglia. In neutrophils is able to
reduce the radical oxygen species production, and Mac-1, IL-8 and COX-2 expression. In T cells,
andrographolide inhibits the expression of IL-2, IFNγ and IL-6, reducing the humoral and cellu‐
lar adaptive immune response. Andrographolide was able to reduce the dendritic cells matura‐
tion and their ability to present antigens to T cells. Andrographolide administered in rodents
reduced the Th2 cytokine IL-4, IL-5, IL-13 and serum immunoglobulin in an ovalbumin in‐
duced asthma model. A reduction of T cells response also has been observed in experimental au‐
toimmune encephalomyelitis and systemic lupus erythematosus mouse model. Several of
immunomodulatory responses have been associated to the inhibition of Nuclear Factor-κB
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functions. It has been demonstrated that andrographolide inhibits the nuclear translocation of
the p65 subunit of NF-κB and interferes with the NF-κB binding to the DNA. Also andrographo‐
lide can reduce NFAT function in T cells and reduce the phosphorylation of signal transducer
and activator of transcription-3 (STAT3) in macrophages.
We propose the potential use of andrographolide in Rheumatoid Arthritis and other autoim‐
mune diseases. This is supported by the fact that andrographolide exerts anti-growth and pro-
apoptotic effects on human rheumatoid arthritis fibroblast- like synoviocytes, the main cellular
constituent of pannus, that combined with a massive infiltration of lymphocytes and macro‐
phages, invades and destroys the local articular structure. Recently, a prospective randomized
placebo-controlled trial has suggested that A. paniculata, a standardized extract containing NLT
30% of andrographolide was effective for symptom relief in patients with Rheumatoid
Arthritis. The use of andrographolide alone or a patented A. paniculata standardized extract in
clinical trials shows mild and few side effects, and has the potential to be developed into a new
alternative drug for Rheumatoid Arthritis treatment in the long term.
2. Andrographis paniculata and labdane diterpenoids
The main and most interesting biological constituent of A. paniculata herb (aerial part) is a
group of diterpene lactones belonging to the ent-labdane class, present in both free and
glycosidic forms, and named andrographolides [1, 2].
Andrographolide is the bitter principle, a colourless, neutral crystalline substance, was first
isolated by Boorsma from different parts of Andrographis paniculata [2]. In 1911 Gorter proved
that it is structurally a lactone and named it andrographolide (in the Chinese literature it is
sometimes cited as andrographis B). The bitter principle has been subjected to a number of
chemical investigations. The properties of the compound and its diterpenoid lactone nature,
as well as its stereochemistry, conformation and crystal structure were cleared by means of
infrared, x, mass spectrometry and NMR analysis. Its chemical formula corresponds to the
3,14,15,18-tetrahydroxy-5,9 H,10-labda-8(20),12-dien-16-oic acid-lactone (Figure 1). Most
recently, various epimers, geometric isomers, and rearrangement products of andrographolide
have been isolated and structurally characterized [3, 4]. Andrographolide, as the other
diterpene lactones of A. paniculata, are generally extracted with CHCl3/EtOH or acetone, and
several methods are described in the literature to determinate its content in the plant, in
commercial formulation, i.e. standardized extract and in biological samples: titration with
alkalis, TLC/UV spectrophotometry and HPLC methods. The maximum content of androgra‐
pholide and related diterpenoids is in the mature leaves. It has been described that the stem
contained 0.2±0.02%, seeds 0.13±0.01%; root 0.44±0.01%; and leaves 2.39±0.008% of androgra‐
pholide [5]. Regional variation in the andrographolide content was also observed. The content
of andrographolide varies with the harvest season. The leaves contain more than 2% androg‐
rapholide before the plant blossoms; afterward the contents decreases to less than 0.5% [2].
The pH modifies the stability of andrographolide, and hydrolysis is extremely slow below pH
7, but considerably faster on the alkaline side, producing some structural changes. Androgra‐
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pholide is sparingly soluble in water; soluble in acetone, methanol, chloroform and ether. As
a water soluble andrographolide derivative, the sodium bisulfite adduct has been synthesized
for medical use as an antipyretic agent.
Preclinical properties include anti-retroviral [6, 7], antiproliferative and pro-apoptotic [8, 9], an‐
ti-diabetic [10, 11], anti-angiogenic [12], anti-thrombotic [13], anti-urothelial [14], anti-leishma‐
niasis [15], hepatoprotective [16, 17], protective activity against alcohol-induced hepatic and







Figure 1. Chemical structure of andrographolide
2.1. Neoandrographolide
The second diterpene isolated from A. paniculata was the minor non-bitter constituent neoan‐
drographolide, which was first described by Kleipool in 1952. The structure of neoandrogra‐
pholide (Figure 2) was described as a diterpene glucoside and its amount in the plant is around
0.5-1%. The main preclinical effects are anti-inflammatory [23, 26, 27], chemosensitizer [28],
anti-herpes-simplex virus [7] and antioxidant [29].
2.2. Minor labdane diterpenes
Afterwards, more than 20 other diterpene lactones, both glycosylated and not, have been
described. The most important among them, characterized by Balmain and Connolly in 1973,
are: 14-deoxy-11,12- didehydroandrographolide, withan average content in the leaf of 0.1%,
14-deoxyandrographolide (0.02%), 14-deoxy-11-oxoandrographolide (0.12%) (Figure 2) [3]. In
other hand has been described that 14-deoxy-11,12- didehydroandrographolide possess
vasorelaxant and antihypertensive [30, 31], anti-herpes [7], antioxidant and hepatoprotective
[32], antithrombotic [33], antiretroviral [6], and antidiabetic properties [34]. Meanwhile 14-
deoxyandrographolide exert hepatoprotective [35], uterine smooth muscle relaxant [36],
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immunomodulator [37], platelet activating factor antagonist [38], and vasorelaxant and
antihypertensive [39] effects. In addition, 14-deoxy-11-oxoandrographolide only has been
reported antileishmaniasis effect [40].
Andrographiside, the 19-glucoside of andrographolide, was isolated in 1981, and only a
hepatoprotective effect has been described [41].
A. paniculata contains also minor andrographolide-like compounds such as andropanoside (19-
glucoside of 14-deoxy-andrographolide), or andrograpanin (3,14-dideoxy-andrographolide),
which are mostly all 14-deoxy- and/or 3-deoxy-derivatives. These compounds show anti-
inflammatory properties in preclinical studies [42, 43].
Isoandrographolide is present in the whole plants and has been described as a cellular
differentiation inducer [3], antiproliferative [44], and cytotoxic [45] effects.
Also three salts of labdanic acids, named as magnesium andrographate, disodium androgra‐
phate and dipotassium andrographate 19-O-D-glucoside have been isolated hydrophylic
extract from the leaf.
Since the total synthesis of andrographolide and analogues, many libraries of new derivatives
have been created using andrographolide as a template with the purpose to obtain compounds
with improved pharmacological profiles. Andrographolide is also a starting point for the
semisynthesis of other labdane diterpenes [46-48].
 


















Figure 2. Chemical structure of minor labdane diterpenes isolated from Andrographis paniculata.
3. Anti-inflammatory and immunomodulatory effects of andrographolide
in vitro and in vivo
Different preparations of A. paniculata administered orally reduced the pyrexia within or after
5 hrs of administration of yeast in rats [49]. On the other hand, administration of A. panicula‐
Innovative Rheumatology250
ta (20 mg/100 g b.w.) one hour before the injection of carrageenin, reduced the edema in 65.3%
in rats. The effect was comparable to oxyphenilbutazone 76.5% [2]
3.1. In vitro studies
Andrographolide, shows anti-inflammatory and anticancer activities in both in vitro and in
vivo. The effects of andrographolide on two cells types that play an important role in the
inflammatory processes, e.g. leukocyte (neutrophils, macrophages and T-cells) and endothelial
cells, demonstrates the ability of this compound to reduce the expression and production of
pro-inflammatory mediators.
Several in vitro  studies show that andrographolide reduces the production of the oxygen
radical superoxide anion and hydrogen peroxide, as well as the adhesion induced by che‐
moattractant in isolated neutrophils [50, 51]. Other antecedents describe a reduction of the
expression of cyclooxygenase-2 (COX-2), inducible enzyme producing prostaglandins, in a
human model of neutrophils [21]. In mouse peritoneal macrophages, andrographolide re‐
duces the production stimulated by lipopolysaccharide (LPS) of two important cytokines
that participate in the amplification and activation of the inflammatory process, the cyto‐
kines tumoral necrosis factor TNFα and granulocyte macrophage colony-stimulating fac‐
tor  (GM-CSF).  The  inhibition  of  the  release  of  these  cytokines  by  andrographolide  was
compared  to  the  synthetic  glucocorticoid  dexamethasone,  showing  andrographolide  to
have a similar effect  as dexamethasone,  but with a lower potency [24,  52].  Also,  the ef‐
fect of andrographolide on the cellular chemotaxis, a response that allows the movement
of  inflammatory cells  to  the injured tissue,  show that  it  reduces  the chemotactic  migra‐
tion of macrophage induced by C5a, which may contribute to its anti-inflammatory activ‐
ity  [53].  In  local  or  systemic  inflammatory  disorders  there  is  an  enhanced formation of
nitric oxide (NO) following the expression of inducible nitric oxide synthase (iNOS). The
inhibition of  NO formation may have therapeutic  benefit  in  patients  with inflammatory
diseases  as  Rheumatoid  Arthritis  [54].  Thus,  andrographolide  reduces  the  LPS-induced
iNOS and COX-2 expression in RAW264.7 macrophages [55, 56]. Additionally, androgra‐
pholide  may  have  an  effect  on  inflammation-mediated  neurodegeneration,  since  it  re‐
duces the production of reactive oxygen species (ROS), TNFα, NO and prostaglandin E2
in microglia, the counterpart of macrophages in the brain [25]. Andrographolide reduces
the  in  vitro  activation  of  human  and  murine  T-cells,  T-cells  proliferation,  interleukin-2
(IL-2) and IFNγ production [57-60].
Interaction of leukocyte-endothelium plays a key role in the initiation and maintenance of
inflammation, being the adhesion molecule ICAM-1 important in mediating leukocyte
adhesion, arrest and transmigration to the inflammatory site. In this respect, certain antece‐
dents show that andrographolide reduces the adhesion of HL-60 cells onto human vein
endothelial cells (HUVEC) and the expression of TNFα-induced ICAM-1[61, 62]. In addition,
andrographolide reduces the endothelial cell proliferation, migration and invasion, suggesting
a role in angiogenesis [63]. Moreover, andrographolide reduces the growth factor deprivation-
induced apoptosis in endothelial cells [64].
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The therapeutic potential of andrographolide for the treatment of rheumatoid arthritis has
been suggested by using of human rheumatoid arthritis fibroblast-like synoviocytes (RAFLSs)
as a cellular model. Andrographolide exerts anti-proliferative and pro-apoptotic effects in
RAFLSs, with G0/G1 cell cycle arrest, increases the expression of cell-cycle inhibitors p21 and
p27 and reduces cyclin-dependent kinase 4 [65].
3.2. In vivo studies
The anti-inflammatory activity of andrographolide has been studied in diverse in vivo
inflammatory diseases models.
Earlier studies with andrographolide show that it inhibited carrageenin, kaolin and nistatin-
induced paw oedema. Moreover, andrographolide p.o. significantly inhibited the weight of
granuloma induced by cotton pellets, and decreased the edema in adjuvant-induced arthritis
(0.1-0.4% dead Mycobacterium tuberculosis suspension). Andrographolide (300 mg/kg) also
inhibited dye leakage in acetic acid-induced vascular permeability. It was devoided of any
ulcerogenic effect on the stomach in acute and chronic studies in rats. These effects were dose
dependent, but inferior to phenylbutazone. Other diterpenic lactones, have shown to possess
antipyretic effect in rabbits and rats with fever induced by 2-4-dinitrophenol. The potency was:
14-deoxy-11,12-didehydroandrographolide > deoxyandrographolide, and neoandrographo‐
lide > andrographolide [66].
In a model of ovalbumin-induced asthma in mice the intra-peritoneal administration of 30 mg/
kg andrographolide reduces the levels of TNFα and GM-CSF (92 and 65 %, respectively) in
bronchoalveolar fluid, and the accumulation of lymphocytes and eosinophils, supporting a
potential use in asthma. Andrographolide also reduced the Th2 cytokine IL-4, IL-5, IL-13 and
serum immunoglobulin [20, 52].
Andrographolide also is helpfulness in the reduction of the symptoms of a mice experimental
autoimmune encephalomyelitis (EAE), an animal model of human Multiple Sclerosis, by
inhibiting T-cell and antibody responses directed to myelin antigens [59]. Similarly, in another
model of autoimmune disease, the administration of andrographlide reduces the susceptibil‐
ity, prevents the symptoms and reduces anti-nuclear antibodies and kidney damage of
systemic lupus erythematous [67, 68].
The potential effect of andrographolide on rheumatoid arthritis could involve angiogenesis
inhibition. In fact, the development of new vessels, is important process that might facilitate
the incoming of inflammatory cells into the synovium and, therefore, stimulate the pannus
formation. [69]. In a model of induction of angiogenesis in C57BL/6 mice, andrographolide
reduced the serum levels of cytokines of IL-1β, IL-6, TNFα and GM-CSF, the angiogenic factor
VEGF and the NO production. Additionally, it is observable an increase of the levels of anti-
angiogenic factors TIMP-1 and IL-2 [12]. Andrographolide also suppresses breast tumor
growth, which correlates with the inhibition of the pro-angiogenic molecules OPN and VEGF,
in the NOD/SCID mice model [70].
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4. Anti-inflammatory molecular mechanisms of andrographolide
All immunomodulatory effects of andrographolide have been attributed to modulation of
different  intracellular  mediators,  however three main mechanisms are commonly descri‐
bed. A first anti-inflammatory mechanism involved in the reduction of COX-2 expression
by andrographolide in neutrophils comprises the modulation of the NF-κB pathway. The
NF-κB is a family of transcription factors that regulate the expression of a large number
of  pro-inflammatory  genes,  such  as  COX-2,  iNOS,  TNF-alpha,  IL-8  or  IL-1,  that  are  in‐
volved in the pathogenesis of Rheumatoid Arthritis. The activation of NF-κB compromis‐
es  two  main  routes:  the  canonical  and  alternative  pathways.  The  canonical  NF-κB
signaling pathway is the most important one. Inflammatory receptor activation results in
IκB kinase (IKK) activation, and the IKK complex phosphorylate the IκB protein, leading
to its polyubiquitination. The ubiquitinated IκB is degraded via 26S proteasome, thereby
exposing the nuclear localization signal on NF-κB dimer and inducing nuclear transloca‐
tion. The alternative NF-κB pathway has been implicated in lymphoid organogenesis and
B cell development, and is based in the processing of p100 NF-κB by IKKα, resulting in
release of the p52 NF-κB bound to RelB [71].
Andrographolide reduces the luciferase activity controlled by NF-κB and inhibits the DNA
binding of NF-κB induced by chemoattractants, however not affecting IκB degradation [21].
The detailed mechanism of DNA binding inhibition indicates that andrographolide form a
covalent adduct with reduced cysteine 62 of p50 subunit NF-κB, which block the binding of
NF-κB to DNA [72]. The NF-κB pathway inhibition by andrographolide has been described in
different cells involving in inflammatory processes such as endothelial cells [62], monocytes
[73], bronchial epithelial cells [20], and dendritic cells [58].
A second mechanism describes an inhibitory effect of andrographolide on iNOS and COX-2
expression in macrophages, attributable to the modulation of transcription factors AP-1 and
STAT3. AP-1 and STAT3, which are important for the production of pro-inflammatory
cytokines such as IL-1β, IL-6 and IL-10, plays a major role in Rheumatoid Arthritis. It has been
reported an overexpression of activated STAT3 and high DNA binding activity of AP-1 in
synovial tissue from patients with Rheumatoid Arthritis [74, 75]. In fact, andrographolide
reduced the LPS-induced AP-1 DNA-binding activities, and also decreased the STAT3
phosphorylation, which is crucial for nuclear translocation and DNA binding [56]. Thus,
andrographolide may also be contributing to reduce the inflammatory process in rheumatoid
arthritis via AP-1 and/or STAT3 modulation.
A third mechanism involves the interference of the transcription factor Nuclear Factor of
Activated T cells (NFAT) induced by andrographolide in T-cells. The interference of NFAT
activation by andrographolide is related to the increase of andrographolide-induced JNK
phosphorylation, which controls the export of NFAT from nucleus [57].
In addition to the immunomodulatory andrographolide mechanism described above, there
are several cellular pathways, such as PI3K/Akt and ERK1/2 pathways, involved in the anti-
inflammatory effect of andrographolide and in the pathogenesis of the Rheumatoid Arthritis
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[76]. The PI3 kinase pathway, is activated by TNF-α and IL-1, within fibroblastic synovial cells,
and can activate the transcription factors NF-κB and AP-1 [77]. Also, the participation of the
ERK1/2 MAPK in the initiation and progression of rheumatoid arthritis suggest that ERK
inhibitors may emerge as a new therapeutic tool. The use of an ERK inhibitor in the animal
model of collagen-induced arthritis suppressed the antigen-specific activation of T cells [78].
In vitro, andrographolide reduced the Akt phosphorylation in macrophages, HUVEC and
microglia, and decreased the ERK1/2 phosphorylation in macrophages, suggesting that the
signaling pathways PI3K/Akt and ERk1/2 may be associated to its anti-inflammatory effect [24,
61, 79]. Additionally, andrographolide also have the ability to reduce ERK1 and ERK5
phosphorylation [57].
In the following figure we propose the main anti-inflammatory effects of andrographolide that
include the inhibition of several intracellular signaling pathways (Figure 3).
Figure 3. Proposed molecular mechanism of andrographolide in inflammation. Andrographolide shows inhibitory effect
(x) on the PI3K/Akt pathway, ERK1/2 MAPK, NF-κB, NFAT, AP-1 and STAT3, and increases the JNK phosphorylation.
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5. Effect of andrographolide on rheumatoid arthritis
5.1. Efficacy of an Andrographis paniculata composition (Paractin®) for the relief of
rheumatoid arthritis symptoms: A prospective randomized placebo-controlled trial
In a prospective, double blind against placebo controlled clinical trial with chronic active
Rheumatoid arthritis, the effect of a standardized patented A. paniculata extract (Paractin®)
administration to 60 patients during 14 weeks in the reduction of symptoms and signs was
studied. Each patient received either a tablet containing 30 mg of andrographolide or a placebo
3 times a day. The demographic characteristic of the patients is shown in table 2.
Treatment groups
Placebo Active drug
Number of patients 28 30
Age (mean years) (min-max) 44.82 (13-63) 47.1 (20-70)
Years with diagnosed (min-max) 6.5 (0.7-22.3) 6.7 (0.7-44.5)
BMI (Kg/m2) (min-max) 30.0 (19.7-41.4) 29.2 (18.3-44.5)
Height (m) (min-max) 1.52 (1.30-1.75) 1.51 (1.38-1.69)
Weight (kg) (min-max) 69.9 (43.0-106.0) 67.2 (39.5-100.0)
Intake of NSAIDs, n (%) 17 (60.7%) 18 (60.0%)
Table 1. Demographic characteristics of Rheumatoid Arthritis patients included in the double blind study of A.
paniculata standardized extract (modified from Burgos et al., 2009).
The results of the study show a significant reduction at the end of the treatment in tender joint,
number of swollen joints, total grade of swollen joint, number of tender joints, total grade of
swollen joints, total grade of tender joints HAQ 0.52 and SF36 (two health questionnaires)
within the group treated with the active drug when comparing day 0 against week 14 (figure
4). The effect was associated to a reduction of rheumatoid factor, IgA, and C4. The study
concludes that the drug was significantly effective in reducing symptoms and serological
parameters of the disease and therefore useful as natural complement in the treatment of
Rheumatoid Arthritis [80].
The clinical efficacy of A. paniculata could be explained by the anti-inflammatory properties of
andrographolide. Andrographolide present in the extract is a potent inhibitors of NF-κB [21],
a transcription factor linked to pro-inflammatory expression of several proteins such as COX-2,
iNOS, and TNF-α, IL-6. Since NF-κB is involved in the pathogenesis of Rheumatoid Arthritis
and other rheumatoid conditions [81], we hypothesized that A. paniculata extract tablets
(Paractin®) can reduce inflammatory symptoms, signs, serological parameters in these
patients. In fact, the clinical findings suggest that the A. paniculata formulation may have an
additional therapeutical effect over Prednisone and MTX in reducing pain and inflammatory
clinical symptoms during treatment period. The beneficial effect in reducing pain and other
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inflammatory symptoms with the A. paniculata formulation could be associated to the high
standardization of total andrographolides (NLT 30%) in the extract considering. This is closely
associated with the inhibition of COX-2 [21] and the reduction of PGE2 production [25], one
of the main mechanisms for the control of inflammation and pain in Rheumatoid Arthritis by
NSAIDs [82]. The dose of Andrographolide used in the present study was around 1.2 mg per
kg. It has been reported that 1mg/kg reaches a steady state plasma concentration of 1.9 μM [83],
a concentration able to reduce the PGE2 production [25]. Moreover, in patients treated with
A. paniculata extract a decrease of rheumatoid factor (RF), creatine kinase, hemoglobin, IgA
and IgM were observed. A correlation between RF titers and clinical disease activity has been
reported widely [84]. RF titers decrease with methotrexate, suggesting an indirect link with
disease activity [85]. Andrographolide can reduce the TNFα production in macrophages, an
effect that could be associated with the reduction of auto-antibodies. It is known that a
reduction of TNFα can diminish significantly the RF levels [86]. The ability of andrographolide
to reduce antibody titer has also been demonstrated in other autoimmune diseases such as
experimental autoimmune encephalomyelitis and lupus (see above). A reduction of immuno‐
globulin, such as IgM and IgA, could also be beneficial in long-term treatment because there
is a positive correlation between the grade of cartilage damage in active Rheumatoid Arthritis
[87] and decrease of RF. Moreover, treatment with DMARDs reduces the level of IgM and IgA
Figure 4. Effect of A. paniculata extract (Paractin®) on tender joints, total grade of tender joints and rheumatoid factor [80].
Innovative Rheumatology256
in patients affected with Rheumatoid Arthritis [85]. We propose that A. paniculata could be
useful in decreasing the radiological progression in long-term treatments of Rheumatoid
Arthritis patients. In support of this, andrographolide reduces NFAT activity, a transcription
factor linked with bone erosion [88]. In MC3T3, a murine osteoblast cell line, we observed that
andrographolide is able to induce differentiation and calcium mineralization, via expression
of COX2 (Burgos et al., data unpublished).
On the other hand, no side effects were observed, indicating that A. paniculata treatment was
safe, non-toxic, and well tolerated. In the literature, side effects associated with A. paniculata
or andrographolide, administered in higher doses (4-6mg/kg), have caused isolated cases of
allergic reactions, tiredness, headache, pruritus/rash, diarrhea, nausea, metallic taste, bitter
taste, dry tongue, eyes sensitive to light, decreased short- term memory, dizziness, heartburn,
tender lymph nodes, and lymphadenopathy [89]. None of these effects were observed in
Rheumatoid Arthritis patients after 14 weeks of treatment [80].
Despite, the fact that was no difference between A. paniculata and placebo treatment after 14
weeks, the intragroup analysis showed a significant decrease of clinical symptoms and
serological parameters in the A. paniculata group. This effect could become more evident in a
long term administration of the drug and follow up Rheumatoid Arthritis patients for several
years.
5.2. Monotherapy with an Andrographis paniculata standardized extract (Paractin®) for the
symptomatic relief of different chronic rheumatoid conditions: A prospective case report
and long term follow up
5.2.1. Background
Presently, there is no specific or etiological cure for Rheumatoid Arthritis and these other
rheumatoid conditions as well, and treatment aims to limit joint damage, prevent loss of
function, and decrease pain. Therapies used for these purposes include nonsteroidal anti-
inflammatory drugs, disease-modifying anti-rheumatic drugs (DMARDs), and corticoste‐
roids. The American College of Rheumatology (ACR) Guidelines recommends the
administration of DMARD within 3 months of diagnosis and methotrexate (MTX) as the
standard treatment in monotherapy or in combination with other DMARDs [90]. MTX, as a
standard therapy, induces significant improvement in the number of tender and swollen joints,
pain, and functional status, in addition to physician and patient global assessment. The onset
of MTX- induced improvement is generally within 3 months in the majority of patients who
will eventually respond, and a plateau in the response is often reached after 6 to 12 months.
However, as an anti-metabolic agent, MTX may cause adverse events such as cytopenia,
serious infections, liver damage and muco-cutaneous problems. The long term use of MTX, is
associated with prevalence of significant liver enzymes in aprox. 13% of the patients and 3.7%
of the patients discontinue MTX permanently for liver toxicity [91]
Considering that  in the clinical  study in patients  with Rheumatoid arthritis  there was a
significant decrease in the group with A. paniculata  in the symptoms over time (after 14
weeks) on the progression of the diseases, it was proposed that long term treatment could
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demonstrate a mayor therapeutic response similar to other DMARs treatment. We report
six case reports, with different rheumatoid arthritis conditions, that support the fact that
A. paniculata  standardized extract  reduces  symptoms of  chronic  joint  pain,  stiffness  and
serological inflammatory parameters in a prospective individual case controlled follow up
study over a period of 42 months.
5.2.2. Intervention
The drug of botanical origin used for the treatment of these cases is a patented (US patent
8084495) standardized extract of A. paniculata known as Paractin®, manufactured and
distributed by Herbal Powers (USA). Paractin® contains andrograpolide NLT 30%, neoan‐
drographolide NLT 0.2% and deoxyandrographolide NLT 3%. Paractin® was supplied
directly for this study and stored according to the instructions of the manufacturer. The batch
number for the A. paniculata extract used in this study was PAR-070801-2. A secondary and
identical batch was retained (No 20050520) and kept at Herbal Powers. Each tablet contained
150 mg of the extract. During all duration of this treatment, two tablets were given before meals
three times a day. This dosage regimen was determined in previous preclinical and clinical
trials with the pure compound and other commercially available A. paniculata extracts [80,
83]. The content of these compounds was evaluated by HPLC using reference standards as
described elsewhere [92].
5.2.3. Patients and method
The group consisted of 6 (five adults and one pediatric) patients, 3 male and 3 female, all with
a long history of active diseases as shown in Table 2.









1 Female 51 Rheumatoid Arthritis 6 50
2 Male 36 Rheumatoid Spondylitis 7 50
3 Female 15 Rheumatoid Arthritis/Vasculitis 3 48
4 Female 39 Psoriatic Arthritis 15 60
5 Male 67 Rheumatoid Arthritis/ Serositis 8 38
6 Male 34 Psoriatic Arthritis/ Erythroderma 4 40
Table 2. Antecedents of patients treated with Andrographis paniculata standardized extract (Paractin®)
All patients were individually recruited and controlled by their treating physician from the
Hospital Regional de Valdivia, Unit of Rheumatology in the city of Valdivia, Chile and
complying confirmed diagnosis of Rheumatoid Arthritis conditions before they were enrolled.
They all signed a written informed consent, including the one pediatric case that was given
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consent by their parents. Advice and indications to test Paractin® was done by the rheuma‐
tologist, who requested the approval of each individual pharmacological protocol and supply
of the product. The rationale and main objective was that Paractin® could reduce long term
clinical symptoms and serological parameters of inflammation in these patients. Inclusion
criteria were confirmed by clinical and laboratory diagnosis, that included active clinical and
serological parameters of inflammation, no underlying standard treatment, poor or no
response to standard treatment, or important side effects of Methotrexate and Prednisone, like
in the female pediatric patient. From day 0, two tablets of Paractin® orally containing 150 mg
of standardized A. paniculata extract (90 mg andrographolide per day) was administered
during 48 month. Total withdrawal of the standard therapy was commonly decided by the
treating physician and patient upon improvement observed with Paractin® treatment and
informed to the investigators. All patients were controlled monthly during the first six months,
then every three months thereafter at their respective place of residence and coordinated by
their rheumatologist. After 24 months the treatment with Paractin® tablets, administered
orally to patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing spondylitis,
reduced symptoms. In a similar fashion the serum immunological parameters of inflammation
were reduced progressively during 48 month of Paractin® treatment.
When Paractin® was given alone; no side effects and good tolerability were observed during
the complete period of administration. Only two cases reported a temporary and early and
Figure 5. Erythrocyte sedimentation rate (ESR) in patients with chronic Rheumatoid Arthritis compared with ESR value
at beginning of treatment. Continuous observation during 48 month. Each point represents the mean and range
(maximum-minimum value). In dashed line the normal value.
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mild gastric discomfort with the tablets. Plasma biochemical parameters showed normal
hematological, liver, kidney and metabolic functions. Interestingly, a moderate reactivation of
joint pain and stiffness in two of the Rheumatoid arthritis patients and the one Ankylosing
spondylitis patient was observed, due to an interruption of the treatment during 15, 11 and 22
days, respectively. Interestingly, these withdrawal and continuity incidents suggest that after
peak and steady efficacy is reached and according to clinical and serological parameters follow
up, a residual activity of the product is maintained between two and three weeks, disappearing
at week four, and then recovered back again to previous status after four weeks. Also, we have
so far not observed any loss of efficacy, or the need to increase dosages of the product, proving
that no adaptation or refractoriness has yet been developed in this treated group. After one to
five years follow up of these six rheumatologic patients, given a daily monotherapy of three
Paractin® – tablets per day, we can conclude this product is well tolerated, safe and efficacious
for the symptomatic relief and serological control of underlying inflammation related to their
disease activity.
Figure 6. C Reactive protein (CRP) in patients with chronic rheumatoid disease compared with the CRP value at the
beginning of treatment with Paractin®. Continuous observation during 48 months. Each point represents the mean
and range (maximum-minimum value). In dashed line the normal value.
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Figure 7. Rheumatoid Factor (RF) in patients with chronic rheumatoid disease treated with Paractin® during 48
month. Each point represents the mean and range (maximum-minimum value). In dashed line the normal value.
Figure 8. Variation on Rheumatologic stiffness in patients with chronic Rheumatoid Arthritis, treated with Paractin®
during 24 month. Each point represents the mean and range (maximum-minimum value).
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Figure 9. Effect of Paractin® on Fatigue in patients with chronic Rheumatoid Arthritis, treated during 24 month. Each
point represents the mean and range (maximum-minimum value).
Figure 10. Effect of Paractin® on pain in patients with chronic Rheumatoid Arthritis, treated during 24 month. Each
point represents the mean and range (maximum-minimum value).
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6. Conclusion
Several studies describe a potent anti-inflammatory action of Andrographis paniculata and
andrographolide. Andrographolide shows a reduction of the production of pro-inflammatory
mediators, such as COX-2, iNOS and cytokines. The molecular mechanism of andrographolide
implies the reduction of the activation of transcription factors as NF-κB, AP-1, STAT3 and
NFAT and the inhibition of intracellular signaling pathways. A. paniculata standardized extract
(30% andrographolide) in clinical trials showed effectiveness for symptom relief and reduce
serological parameters in patients with Rheumatoid Arthritis, and the data support a long term
treatment similar to other DMARDs.
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